Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Other Accumulated Expenses (2016 - 2023)

ProQR Therapeutics' Other Accumulated Expenses history spans 4 years, with the latest figure at $5.2 million for Q3 2023.

  • On a quarterly basis, Other Accumulated Expenses fell 62.05% to $5.2 million in Q3 2023 year-over-year; TTM through Sep 2023 was $5.2 million, a 62.05% decrease, with the full-year FY2022 number at $8.9 million, down 30.4% from a year prior.
  • Other Accumulated Expenses hit $5.2 million in Q3 2023 for ProQR Therapeutics, up from $4.4 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for PRQR hit a ceiling of $13.8 million in Q3 2022 and a floor of $6502.8 in Q1 2021.
  • Historically, Other Accumulated Expenses has averaged $7.7 million across 4 years, with a median of $8.1 million in 2020.
  • Biggest five-year swings in Other Accumulated Expenses: surged 138353.7% in 2022 and later crashed 62.05% in 2023.
  • Tracing PRQR's Other Accumulated Expenses over 4 years: stood at $7.3 million in 2020, then surged by 68.75% to $12.3 million in 2021, then dropped by 28.0% to $8.9 million in 2022, then crashed by 40.87% to $5.2 million in 2023.
  • Business Quant data shows Other Accumulated Expenses for PRQR at $5.2 million in Q3 2023, $4.4 million in Q2 2023, and $5.3 million in Q1 2023.